Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
the main purpose:
- Evaluate the safety and resistance of BAT6026 injection as a single agent in the
treatment of patients with locally advanced or metastatic solid tumors Acceptability
- Explore maximum tolerated dose (MTD) or maximum administered dose (MAD) and be phase II
or follow-up clinical The study provides recommended doses and reasonable dosing
schedules.
Secondary purpose:
- Evaluate the single dose and multiple doses of BAT6026 injection in patients with
locally advanced or metastatic solid tumors Pharmacokinetic (PK) characteristics of the
drug;
- Evaluate the immunogenicity of BAT6026 injection;
- Evaluate the pharmacodynamic properties of BAT6026 injection;
- Preliminary evaluation of the anti-tumor efficacy of BAT6026 injection.